Q-omics provides the consensus-scored TRANK1 profile across patient tissues and cancer cell-line models. TRANK1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRANK1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRANK1 RNA expression shows 20,972 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where TRANK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRANK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRANK1 survival associations across molecular data types. TRANK1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRANK1 RNA expression–survival associations across cancer types. High TRANK1 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, BRCA, CESC and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRANK1 RNA expression.
This table summarizes TRANK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRANK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRANK1 shows lower tumor expression in COAD, LUSC and UCEC and higher tumor expression in KIRC, HNSC and KIRP. The KIRC box plot shows higher TRANK1 RNA expression in tumor versus normal tissue (log2 FC = +1.078, t-test p < 0.001).
This table shows molecular features associated with TRANK1 in patient tissues and cancer cell lines. In patient samples, TRANK1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRANK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
